Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-728-T in HIV Infected Subjects
NCT01252641Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Nov 2010
- Primary completion
- Dec 2014
- Modality
- Gene Silencing, Zinc Finger Nucleases, Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of SB-728-T in human immunodeficiency virus infection (HIV), sponsored by Sangamo Therapeutics. Started Nov 2010; status: completed.
02
Drugs
SB-728-T
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01252641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01252641.